Unveiling the Hidden Driver: How Glycolytic Pathways Fuel Systemic Inflammation in Dermatomyositis
A groundbreaking study reveals a surprising culprit behind the systemic inflammation associated with dermatomyositis (DM): metabolic reprogramming in the skin. Researchers have discovered that this process, rather than immune cells, plays a central role in the inflammation that affects the entire body. This finding opens up exciting possibilities for novel therapies targeting the underlying metabolic dysfunction.
The Skin's Role in Systemic Inflammation
By examining skin samples from adults with DM at a single-cell resolution, the research team made a remarkable discovery. They found that fibroblasts, not immune cells, are the primary signaling hubs within inflamed skin. These specialized fibroblasts, known as "inflammatory fibroblasts," exhibit strong activation of the type I interferon (IFN-I) pathway, a hallmark of immune dysregulation. This activation is linked to elevated expression of the chemokine CXCL10, a key player in the inflammatory response.
A Novel Axis Uncovered: CXCL10–Glycolysis
The study identified a groundbreaking "CXCL10–glycolysis axis" as a core mechanism driving inflammation. Proteomic and transcriptomic data from both skin and blood revealed a correlation between increased glycolytic activity in inflammatory fibroblasts and systemic inflammatory signals. This metabolic shift appears to amplify immune activation beyond the skin, linking local pathology to systemic disease burden.
Preclinical evidence further supports the idea that metabolic reprogramming is a driver of disease. In a model of autoimmune myositis, inhibiting glycolysis using 2‑deoxy‑D‑glucose (2DG) significantly reduced inflammation. These findings suggest that targeting cellular metabolism, particularly glycolysis, might offer a promising new therapeutic avenue for DM.
Challenging Traditional Views and Shaping Future Research
This study challenges the traditional view that immune cells are solely responsible for DM skin inflammation, highlighting the central role of fibroblasts and metabolic dysfunction. The link between skin-level changes and systemic inflammation emphasizes the importance of holistic disease management. The authors call for further research into metabolism-targeted treatments and suggest integrating metabolomic and proteomic profiling into routine care to better stratify patients and personalize therapy.
This research, published in the British Journal of Dermatology, opens up exciting possibilities for novel therapies and a deeper understanding of DM. The Creative Commons Attribution-Non Commercial 4.0 License governs the availability of each article.
